NEW YORK – Johns Hopkins University spinout Delfi Diagnostics has staked its claim in the growing push to harness genomic and epigenomic technologies for non-invasive early cancer detection and screening.
Announcing a $100 million financing on Tuesday, the company emerged from what has been a quiet period since its founding in 2019, disclosing plans to use the funding to support clinical validation of its technology through prospective studies.